share_log

Corvus Pharmaceuticals Announces FDA Fast Track Designation For Soquelitinib In Treatment Of Relapsed Or Refractory PTCL; Phase 3 Clinical Trial To Begin Initial Enrollment In Q3 2024

Benzinga ·  Aug 1 20:41
Corvus Pharmaceuticals Announces FDA Fast Track Designation For Soquelitinib In Treatment Of Relapsed Or Refractory PTCL; Phase 3 Clinical Trial To Begin Initial Enrollment In Q3 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment